Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 26;37(14):1169–1178. doi: 10.1200/JCO.18.00925

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 3. — Association between cyclin E1 (CCNE1) mRNA expression and palbociclib (PAL) efficacy. (A) Progression-free survival (PFS) in tumors with low or high CCNE1 mRNA expression by median. Hazard ratios (HRs) were derived from a Cox proportional hazards regression model. P value from the interaction test between gene expression and treatment. (B) Subpopulation treatment effect pattern plot analysis of CCNE1 mRNA expression as measured by HR (PAL plus fulvestrant [FUL] v placebo [PBO] plus FUL). The x-axis represents the median CCNE1 mRNA expression for patients in each overlapping subpopulation. The dashed lines represent the corresponding 95% pointwise CIs. The solid black line indicates a reference HR of 1, with HR less than 1 favoring the PAL plus FUL combination. (C) Subpopulation treatment effect pattern plot analysis of CCNE1 mRNA expression as measured by 6-month PFS rates. mPFS, median progression-free survival.